Notable advances have been achieved in the treatment of cancer since the advent of
immunotherapy, and immune checkpoint inhibitors have shown clinical benefit across a …

Immune checkpoint inhibitors (ICIs) have demonstrated to be highly efficient in treating solid
tumors; however, many patients have limited benefits in terms of response and survival. This …

Background Lung cancer (LC) is one of the most aggressive, prevalent and fatal
malignancies. Gut microbes and their associated metabolites are thought to cause and …

Simple Summary Inflammation is like the proverbial double-edged sword. Controlled short-
term inflammation could be a protective response while uncontrolled inflammation sustains …

Improving tumor immunogenicity is critical for increasing the responsiveness of triple-
negative breast cancer (TNBC) to anti-PD-(L) 1 treatment. Here, we verified that chidamide …

Simple Summary Tumor heterogeneity promotes the development of drug resistance in
cancer. HDAC inhibitors modulate several processes that contribute to intra-tumoral …

Purpose: The limited efficacy of chimeric antigen receptor (CAR) T-cell therapies with solid
malignancies prompted us to test whether epigenetic therapy could enhance the antitumor …

Programmed cell death protein 1 (PD-1) is a type of immune-inhibitory checkpoint protein,
which delivers inhibitory signals to cytotoxic T cells by binding to the programmed death …

The molecular mechanisms by which tumor cells survive or die following therapeutic
interventions are complex. There are three broadly defined categories of cell death …

Introduction: Despite diverse treatment modalities and novel therapies, many cancers and
patients are not effectively treated. Cancer immunotherapy has recently achieved …